Royalty Pharma PLC (NASDAQ:RPRX) Announces Quarterly Dividend of $0.23

Royalty Pharma PLC (NASDAQ:RPRX) declared a quarterly dividend on Friday, October 16th. Shareholders of record on Friday, November 13th will be given a dividend of $0.2350 per share by the biopharmaceutical company on Thursday, December 10th. This represents a $0.94 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date of this dividend is Friday, November 13th.

Royalty Pharma has increased its dividend payment by an average of 0.2% annually over the last three years and has raised its dividend annually for the last 5 consecutive years. Royalty Pharma has a dividend payout ratio of 18.7% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Royalty Pharma to earn $5.63 per share next year, which means the company should continue to be able to cover its $0.94 annual dividend with an expected future payout ratio of 16.7%.

Royalty Pharma Trading Up 2.2%

RPRX stock traded up $1.34 during mid-day trading on Friday, hitting $60.96. 5,786,437 shares of the company were exchanged, compared to its average volume of 3,083,702. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $35.05 billion, a P/E ratio of 42.04, a PEG ratio of 1.63 and a beta of 0.42. The business has a fifty day simple moving average of $59.42 and a 200-day simple moving average of $55.71. Royalty Pharma has a 12-month low of $35.92 and a 12-month high of $64.38.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. The business had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. On average, equities research analysts predict that Royalty Pharma will post 5.29 earnings per share for the current fiscal year.

Royalty Pharma Company Profile

Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.